You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

Article metrics

Article menu

Download PDFPDF

XML
Late-breaking abstracts
Clinical trials completed
797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

 

Online download statistics by month:

Online download statistics by month: November 2020 to April 2022

AbstractFullPdf
Nov 2020161019
Dec 20208208
Jan 20213104
Feb 20213202
Mar 20217506
Apr 20215108
May 202132010
Jun 2021309
Jul 20210014
Aug 2021307
Sep 20212056
Oct 202194055
Nov 2021112025
Dec 20213600
Jan 20229109
Feb 202267010
Mar 202298014
Apr 2022149014
Total11190270